An HTLV-I/II Vaccine: From Animal Models to Clinical Trials?
The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
A human T-lymphotropic virus type I/II (HTLV-I/II) vaccine is necessary in view of two etiologically related, life-threatening diseases, namely, adult T-cell leukemia/lymphoma and tropical spastic paraparesis/HTLV-I-associated myelopathy. When the risk of developing autoimmune diseases such as uveitis, polymyositis, and arthritis is included, one can estimate the life-long risk of infected individuals to develop an HTLV associated pathology as approximately 10%. The populations at risk are, in a large majority, from developing countries but the epidemic of HTLV-II infection in intravenous drug users (IVDU) represents a possible reservoir for dissemination in the general population. The number of HTLV-I-infected individuals (15 to 25 million), together with the severity of associated disease, justifies the development of a vaccine. Different vaccine preparations have been developed, using mostly recombinant pox and adenoviruses, but DNA plasmid technology will soon become a feasible approach. Various animal models exist for experimental viral infections, involving rats, rabbits, or monkeys, but up to now, neither hematological nor neurological disorders have been induced by HTLV infection in such animal models. For long-term protection from HTLV-I-associated diseases, vaccination should induce both neutralizing antibodies and specific cell-mediated immunity. This will require the incorporation of both env and gag coding sequences in the vaccine preparations. Preventive clinical trials may involve different cohorts of seronegative young girls from endemic areas prior to sexual activity and IVDU in the industrialized world. In parallel, one should consider therapeutic vaccine trials in HTLV-I-positive mothers and IVDU to protect them against disease development. The observed rate of seroconversion in these different cohorts makes such trials feasible.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Infectious transmission of human T‐cell leukemia virus to rabbits
Miyoshi, I., Yoshimoto, S., Kubonishi, I., Fujishita, M., Ohtsuki, Y., Yamashita, M., Yamato, K., Hirose, S., Taguchi, H., Niiya, K., et al. (1985) · International Journal of Cancer · doi:10.1002/ijc.2910350113 · Cited by 72
Cited by
Global epidemiology of HTLV-I infection and associated diseases
Proietti, F. A., Carneiro-Proietti, A. B. F., Catalan-Soares, B. C., & Murphy, E. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208968 · Cited by 1,008
Human T-lymphotropic virus 1: recent knowledge about an ancient infection
Verdonck, K., González, E., Van Dooren, S., Vandamme, A.-M., Vanham, G., & Gotuzzo, E. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70081-6 · Cited by 661
Epidemiology, treatment, and prevention of human T-cell leukemia virus type 1-associated diseases
Gonçalves, D. U., Proietti, F. A., Ribas, J. G. R., Araújo, M. G., Pinheiro, S. R., Guedes, A. C., & Carneiro-Proietti, A. B. F. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00063-09 · Cited by 478
Human T-lymphotropic virus type I infection
Manns, A., Hisada, M., & Grenade, L. L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)09460-4 · Cited by 360
Human T Lymphotropic Virus Type 1 (HTLV-1): Molecular Biology and Oncogenesis
Kannian, P., & Green, P. L. (2010) · Viruses · doi:10.3390/v2092037 · Cited by 139
Metadata
- Authors
- de Thé, G., & Kazanji, M.
- Venue
- Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology
- Published
- 1996
- Volume
- 13
- Pages
- S191-S198
- ISSN
- 1077-9450 (ISSN-L)
- OpenAlex
- W2022861197
- Cited by
- 75
- References
- 1
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: An HTLV-I/II Vaccine: From Animal Models to Clinical Trials? https://app.cochat.ai/papers/10.1097/00042560-199600001-00029
- The paper
- de Thé, G., & Kazanji, M. (1996). An HTLV-I/II Vaccine: From Animal Models to Clinical Trials? Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology. https://doi.org/10.1097/00042560-199600001-00029
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.